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Abstract  
 
There is growing evidence that patients with type 2 diabetes mellitus have increased cancer 
risk. We examined the association between diabetes, cancer, and cancer-related mortality and 
hypothesized that insulin sensitizers lower cancer-related mortality. Participants in the 
Diabetes Cardiovascular Risk and Evaluation: Targets and Essential Data for Commitment of 
Treatment study, a nationwide cross-sectional and prospective epidemiological study, were 
recruited from German primary care practices. In the cross-sectional study, subjects with type 
2 diabetes mellitus had a higher prevalence of malignancies (66/1308, 5.1%) compared to 
nondiabetic subjects (185/6211, 3.0%) (odds ratio, 1.64; 95% confidence interval, 1.12-2.41) 
before and after adjustment for age, sex, hemoglobin A1c, smoking status, and body mass 
index. Patients on metformin had a lower prevalence of malignancies, comparable with that 
among nondiabetic patients, whereas those on any other oral combination treatment had a 2-
fold higher risk for malignancies even after adjusting for possible confounders; inclusion of 
metformin in these regimens decreased the prevalence of malignancies. In the prospective 
analyses, diabetic patients in general and diabetic patients treated with insulin (either as 
monotherapy or in combination with other treatments) had a 2- and 4-fold, respectively, 
higher mortality rate than nondiabetic patients, even after adjustment for potential 
confounders (incidence of cancer deaths in patients with type 2 diabetes mellitus [2.6%] vs 
the incidence of cancer deaths in patients without type 2 diabetes mellitus [1.2%]). Our results 
suggest that diabetes and medications for diabetes, with the exception of the insulin sensitizer 
metformin, increase cancer risk and mortality.    
 
1. Introduction  
 
Epidemiological evidence is linking type 2 diabetes mellitus with several types of cancer, 
including hepatocellular, pancreatic, endometrial, colon, bladder, and breast cancer [1-3]. This 
is concerning because the incidence of type 2 diabetes mellitus is rising due to the aging 
population and the obesity epidemic [4]. Obesity, closely associated with the development of 
type 2 diabetes mellitus, also leads to an increased risk of many cancers [5].  
 
The mechanisms linking diabetes and cancer have not been fully elucidated, but both 
hyperglycemia and hyperinsulinemia have been implicated. Insulin, through binding to the 
insulin and/or insulin-like growth factor, stimulates cell proliferation in vitro [3]. 
Observational studies in humans have shown an increased risk for cancer and cancer mortality 
in patients taking exogenous insulin and insulin secretagogues such as sulfonylureas [6-9]. In 
contrast, use of metformin, an insulin sensitizer that reduces circulating insulin levels, has 
been shown to significantly decrease the risk of cancer, cancer mortality, and cancer 
progression [10-13]. Evidence regarding other medications such as the thiazolidinediones or 
acarbose is conflicting but suggests that they do not alter cancer incidence [3,13].  
 
Importantly, randomized controlled trials, which provide the highest quality evidence, have 
not supported an association between insulin therapy and cancer incidence or mortality [14]. 
Most of the reported evidence on the effect of antidiabetic treatment on cancer incidence or 
progression comes from either retrospective or case-control observational studies that do not 
incorporate the time sequence criterion for causality. There are only 3 prospective cohort 
studies and, importantly, only one retrospective cohort study with a nationwide population 
and primary care–based design, based on the British population [7].  
 
No prior study has explored the effect of different treatment modalities in type 2 diabetic 
patients using both cross-sectional and longitudinal analyses providing joint evaluation of 
several antidiabetic medications with and without adjustments for several potential 
confounders in the context of a nationwide community-based study.  
 
The aim of the present work is to investigate associations between antidiabetic therapies and 
the prevalence of and mortality from cancer in diabetic patients followed in primary care 
clinics randomly selected throughout Germany, in the context of a nationwide, population-
based prospective cohort study.  
 
2. Methods  
 
The research received institutional approval from the bioethics committee of the Technische 
Universitaet Dresden. All patients provided informed consent before participating in the 
study.  
 
2.1. Study population  
 
Participants in the Diabetes Cardiovascular Risk and Evaluation: Targets and Essential Data 
for Commitment of Treatment (DETECT) study, a large cross-sectional and prospective 
epidemiological study, were recruited from German primary care practices. The study was 
initiated to investigate the prevalence and comorbidity of diabetes mellitus, hypertension, 
dyslipidemia, coronary heart disease, and other associated medical conditions and behavioral 
and clinical risk factors. Methods, design, and previous results have been published in detail 
elsewhere [15-17]. In brief, a nationwide sample of 7053 randomly selected primary care 
physicians in Germany were invited to take part in a pre-study in the first quarter of 2003. The 
response rate was 60.2%, yielding a total of 3795 physicians. Of these, 3188 opted to take part 
in the main study. The sample was representative of primary care physicians in Germany in 
terms of regional distribution, age, years of experience, specialty orientation, and patient load 
per day [17].  
 
On a target day in September 2003, the enrolled primary care physicians recorded the health 
state of 55 518 consecutively enrolled patients (response rate 93.5%) by using an extensive 
standardized physician clinical interview and a patient self-report questionnaire.  
 
For the longitudinal arm of this study, a random subset of 7519 patients who had undergone a 
more intensive standardized laboratory assessment was included. They were followed after 1 
year in 2004and after 5 years in 2007 to 2008.Thirty-seven patients with type 1 diabetes 
mellitus were excluded, leaving 7482 patients for the baseline, cross-sectional analyses.  
 
For the prospective analyses, 693 participants were lost to follow-up and did not provide 
information regarding cancer-related mortality. Baseline characteristics of the excluded 
patients were not statistically significantly different from the rest of the group. This left 6826 
patients for the prospective study.  
 
2.2. Assessment of clinical and laboratory variables  
 
Type 2 diabetes mellitus was defined by the clinicians indicating a “definite” diagnosis of 
diabetes mellitus or the use of antidiabetic medications recorded by the clinician in the 
standardized clinical interview. The diagnosis of cancer and the type of cancer were based on 
clinicians rating the diagnosis as “definite.” Both diagnoses of “cancer” and “type 2 diabetes” 
were confirmed using nosologic criteria from the International Statistical Classification of 
Diseases and Related Health Problems, 10th Revision. Cancer-related mortality was reported 
by the clinician and reconfirmed by examination of death certificates. Smoking status was 
based on physicians' reports in the standardized clinical interview.  
 
Height and weight were measured by the physicians using a standardized protocol [15], and 
body mass index (BMI) was calculated accordingly.   
 
Standardized blood samples and a defined set of laboratory markers were collected between 
8:00 and 10:00 AM in the fasting state, and transported at room temperature within 24 hours 
to the study's central laboratory at the Medical University of Graz, Austria. After arrival, the 
samples were centrifuged immediately and serum and plasma were stored at −80°C until 
further processing [17]. Hemoglobin A1c (HbA 1c) was determined chromographically using 
the Arkray ADAMS A1c HA-8160 analyzing system (Arkray, Kyoto, Japan), using secondary 
standards as recommended by the manufacturers [15,17].  
 
2.3. Statistical analysis  
 
All statistical analyses were performed using STATA 11.0 (Stata, College Station, TX).  
 
A summary of the study variables and descriptive characteristics are presented as mean ± SD 
or as number of patients and percentages. Baseline characteristics between patients with 
cancer vs patients without cancer and patients with type 2 diabetes mellitus vs those without 
type 2 diabetes mellitus were compared using t test for continuous variables and Pearson χ2 
test for categorical variables.  
 
Logistic regression analyses were applied to study the cross-sectional association of cancer 
with type 2 diabetes mellitus or diabetes therapy. Odds ratios and 95% confidence intervals 
(CIs) were presented for unadjusted and adjusted models. Cancer-related mortality was 
modeled by Cox regression analyses with follow-up duration as the time variable. Hazard 
ratios and 95% CIs were presented for unadjusted and adjusted models. The proportional 
hazard assumption was confirmed by Schoenfeld residuals. Covariates included in the 
adjusted models include age, sex, HbA1c, smoking status, and BMI at baseline. Two-sided P 
values less than .05 were used to infer statistical significance.  
 
3. Results  
 
3.1. Baseline cohort description and cross-sectional analyses  
 
The baseline characteristics of the study sample are reported in Table 1; 1308 (17.4%) 
patients had type 2 diabetes mellitus and 251 (3.3%) had cancer at baseline. The prevalence of 
cancer was 5.1% in patients with type 2 diabetes mellitus and 3.0% in patients without type 2 
diabetes mellitus (P < .001). The subgroup of patients with type 2 diabetes mellitus and 
cancer had a mean age of 70.4 ± 8.0 years; a mean BMI of 28.3 ± 4.2 kg/ m2; and the mean 
levels of HbA1c and plasma glucose were 6.4% ± 1.0% and 130.2 ± 45.0 mg/dL, respectively. 
In contrast, patients without cancer in the type 2 diabetes mellitus group at baseline were 66.4 
± 10.0 years old and had a mean BMI, HbA1c, and plasma glucose of 29.8 ± 5.0 kg/m2, 6.8 ± 
1.2, and 147.8 ± 56.0 mg/dL, respectively. The differences in age, plasma glucose, and 
HbA1c remained statistically significant after adjustment for sex, BMI, and/or age (where 
appropriate), whereas the difference of BMI was not statistically significant after adjustment.  
 
The proportion of diabetic patients receiving any antidiabetic treatment was 60.9% in patients 
with cancer compared with 74.9% (P = .014) in those without cancer. The insulin and 
metformin treatment rates were lower in the subgroup of patients with type 2 diabetes mellitus 
and cancer compared with those in patients without cancer (insulin, 18.8% vs 27.1%; 
metformin, 31.3% vs 42.4%), but this difference did not remain significant after controlling 
for age, BMI, and HbA1c (data not shown). Table 2 presents the cross-sectional analyses. At 
baseline, 251 patients had cancer, 66 of whom also had type 2 diabetes mellitus. Hence, the 
odds ratio (OR) for having cancer was 1.72 (95% CI, 1.29-2.29) in patients with type 2 
diabetes mellitus compared with that in patients without diabetes, which remained statistically 
significant even after adjusting for age, sex, HbA1c, smoking, and BMI (OR, 1.64; 95% CI, 
1.12-2.41).  
 
Patients with type 2 diabetes mellitus who received monotherapy with insulin had an OR of 
0.93 (95% CI, 0.41-2.13) for cancer compared to patients without diabetes. Similarly, when 
examining all patients taking insulin (monotherapy or combination therapy), the OR was 1.08 
(95% CI, 0.59-1.95) for having cancer. However, any other monotherapy or combination 
treatment excluding insulin was associated with an elevated OR of 1.51 (95% CI, 1.00-2.28) 
compared to that in patients without diabetes. Similar results were found when only those on 
combination treatment with insulin and another agent and those on combination treatment 
with oral antidiabetic agents are compared to patients without type 2 diabetes mellitus.  
 
Compared to patients without diabetes mellitus, patients with type 2 diabetes mellitus on 
monotherapy with metformin tended to have lower cancer prevalence (OR, 1.04; 95% CI, 
0.46- 2.39) than patients not on metformin therapy (OR, 1.44; 95% CI, 0.89-2.34). When 
looking at all patients who are treated with metformin, including both monotherapy and 
combination therapy, the OR was 1.19 (95% CI, 0.7-2.04) compared to that in patients 
without type 2 diabetes mellitus. This compared to an OR of 2.26 (95% CI, 1.24-4.13) for 
patients taking any other diabetes treatment excluding metformin, which was statistically 
significant in the crude analysis compared to the OR for patients without type 2 diabetes 
mellitus. Furthermore, patients with monotherapy or combination treatment excluding 
metformin had a higher proportion of cancer (OR, 1.89; 95% CI, 0.87-4.13) compared to 
patients with type 2 diabetes mellitus and monotherapy or combination treatment including 
metformin (data not shown).  
 
Restricting the analysis to those taking only oral medications, a higher OR for cancer was 
seen in those on combination treatment with any oral medication excluding metformin (OR, 
3.88; 95% CI, 1.16-12.98), which persisted after multivariate adjustment (OR, 4.04; 95% CI, 
1.07-15.26). For those on any oral medication including metformin, the OR was 1.32 (95% 
CI, 0.67-2.61) compared to that in patients without type 2 diabetes mellitus, respectively.  
 
Treatment with glucosidase inhibitors, sulfonylureas, or meglitinides increased the risk for 
malignancies by 1.59-fold (95% CI, 1.01-2.5) compared to patients without type 2 diabetes 
mellitus. This increase did not persist after adjustment for multivariate confounders. Patients 
with type 2 diabetes mellitus and monotherapy with metformin had a lower proportion of 
cancer (OR, 0.66; 95% CI, 0.26-1.64) compared to patients with type 2 diabetes mellitus and 
treatment with glucosidase inhibitors, sulfonylureas, or meglitinides (data not shown).  
 
3.2. Prospective cohort analyses  
 
Table 3 presents the data relating to cancer-related mortality data at the 4- to 5-year follow-
up. The cancer-related mortality rate was 1.2% (n = 68) in subjects without type 2 diabetes 
mellitus and 2.6% (n = 32) in subjects with type 2 diabetes mellitus (hazard ratio [HR], 2.10; 
95% CI, 1.38-3.20).  
 
In patients treated with insulin monotherapy, the crude HR was 4.03 (95% CI, 2.08-7.83) and 
the association remained significant after adjusting for confounders (HR, 3.87; 95% CI, 1.53-
9.81). Similar findings, including persistent significance after adjustment for confounders, 
were seen when considering all patients who were taking any monotherapy or combination 
treatment including insulin (HR, 4.24; 95% CI, 2.52-7.12) or any combination treatment 
including insulin (HR, 4.52; 95% CI, 2.18-9.40).  
 
The HR for cancer-related death in patients on monotherapy with metformin (HR, 1.34; 95% 
CI, 0.42-4.25) was lower than the HR in patients who were on any other treatment regimen 
that did not include metformin (crude HR, 3.51; 95% CI, 2.09-5.88; confounder-adjusted HR, 
2.51; 95% CI, 1.2-5.27). Similar results were seen when looking at any treatment regimen that 
included metformin or that did not include metformin. If looking only at oral combination 
treatment regimens, those that did not include metformin had a HR for mortality of 7.36, 
which approached significance after multivariate analysis (HR, 3.66; P = .09).  
 
Treatment with glucosidase inhibitors, sulfonylureas, and meglitinides was associated with 
increased mortality when compared to that in patients without type 2 diabetes mellitus (HR, 
1.88; 95% CI, 0.97-3.63). Compared to treatment with glucosidase inhibitors, sulfonylureas, 
and meglitinides, patients with type 2 diabetes mellitus and monotherapy with metformin had 
a lower cancer-related mortality (HR, 0.71; 95% CI 0.2-2.59) (data not shown).  
 
 
4. Discussion  
 
We have studied a large, nationwide primary care–based cohort, representative of German 
primary care practices, to identify the prevalence of malignancies among patients with type 2 
diabetes mellitus, cross-sectional associations between specific antidiabetic treatments and 
prevalence of malignancies, as well as prospective associations between type 2 diabetes 
mellitus, diabetes-specific treatments, and cancer mortality.  
 
Subjects with type 2 diabetes mellitus had a higher prevalence of malignancies compared to 
nondiabetic subjects in the same primary care practices (OR, 1.64; 95% CI, 1.12-2.41) before 
and after adjustment for age, sex, HbA1c, smoking status, and BMI. Moreover, we found that 
patients on oral medications including glucosidase inhibitors, sulfonylureas, and meglitinides 
had a prevalence of malignancies that is similar to that observed for all patients with type 2 
diabetes mellitus, that is, nearly 2-fold higher than in nondiabetic patients. In contrast, patients 
on the insulin sensitizer metformin had a relatively lower prevalence of malignancies, which 
was comparable to that observed among nondiabetic patients. Similarly, patients on any 
combination treatment including oral medications other than metformin had a 2-fold higher 
risk for malignancies even after adjusting for possible confounders, whereas inclusion of 
metformin in any combination regimen decreased the prevalence of malignancies to that of 
nondiabetic patients.  
 
Interestingly, in our study, patients on insulin had a similar prevalence of malignancies to the 
nondiabetic patients but considerably higher mortality in prospective follow-up, suggesting 2 
possible underlying mechanisms. Either insulin exposure does not initiate carcinogenesis, but 
may play a role in stimulating cancer growth and accelerating growth over time, or insulin 
therapy may cause higher mortality through other mechanisms.  
 
Furthermore, in the prospective analyses, we showed that diabetic patients in general have a 
2-fold higher cancer mortality than nondiabetic patients and that among diabetic patients, 
those treated with insulin (either as monotherapy or in combination with other treatments) 
have a 4-fold higher cancer-related mortality that remained significant after adjustment for 
potential confounders including age, sex, BMI, smoking status, and glycemic control. 
Monotherapy or combination therapy with any oral medications for type 2 diabetes mellitus, 
except metformin, was associated with increased mortality by several-fold, whereas 
monotherapy with metformin resulted in mortality comparable to that in nondiabetic patients. 
Monotherapy and/or oral combination treatment including metformin reduced the mortality 
rate to levels comparable to those seen in patients without type 2 diabetes mellitus.  
 
On the other hand, metformin might more likely be prescribed in the beginning of the therapy 
strategy for patients with type 2 diabetes mellitus; it might be possible that these cases are at 
lower cancer risk because of their yet milder disease.  
 
The suppression of hepatic glucose production is seen as the major action of metformin. In 
addition, it has anti-inflammatory and antioxidant properties. Nath et al [18] recently 
emphasized this very important role with metformin-induced activation of adenosine 
monophospate-activated protein kinase in the brains of mice with experimental autoimmune 
encephalomyelitis and in macrophages. Metformin inhibited the expression of inflammatory 
cytokines and their mediators [18].  
 
Our study adds to an emerging literature on the interactions between diabetes mellitus and 
cancer. We confirm findings from other recent studies reporting an increased risk of cancer, 
increased cancer-related mortality, and increased overall mortality in diabetic patients 
compared to nondiabetic patients [1,19,20].  
 
A number of studies have examined the association between antidiabetic agents and the 
increased prevalence of cancer and cancer-related mortality in diabetic patients. Despite some 
inconsistency in the results, case-control studies [10,13], retrospective cohort studies [7-9], 
and prospective cohort studies [6,11,12] have mostly shown an association between exposure 
to insulin or insulin secretagogues and increased prevalence of cancer [8,13], increased 
cancer-related mortality [6], and increased progression of solid tumors [7,9]. In contrast, 
exposure to metformin appears to be neutral or protective, with a reduced prevalence of 
cancer [12] and reduced cancer-related mortality [11,12]. However, there have been several 
other studies that have failed to show increased cancer mortality in patients taking insulin 
[11,12] or a sulfonylurea [12].  
 
The findings from our study appear to support the theory that the increased risk of cancer 
mortality in diabetic patients is related to hyperinsulinemia and the effect of insulin on cell 
proliferation, whereas metformin, which decreases insulin resistance and hyperinsulinemia, 
has a protective effect. Data from emerging randomized clinical trials are limited by the 
duration and size of these trials [14], whereas data from prior observational studies are, by 
design, confounded by either known and/or unknown confounders that could not be controlled 
for. Patients who are taking insulin are likely to be sicker and have more complications from 
their diabetes, as insulin treatment is usually initiated later in the course of the disease. Hence, 
their cancer may have progressed more and/or they may be less able to tolerate cancer-related 
complications or anticancer treatments. Similarly, metformin is the recommended first-line 
therapy for diabetes mellitus and has multiple contraindications limiting its use in people with 
comorbidities, hence introducing a bias for the healthiest patients. Because the gold standard 
of clinical trials is difficult to perform in the near future, community and primary case– based 
prospective cohort studies can reduce or eliminate some important confounding factors.  
 
Our study has several strengths. Unlike most other studies, this prospective cohort is 
community-based and encompasses a large geographic area in central Europe. There is only 
one previous nationwide prospective cohort study that was population-based [7]. Our study is 
a nationwide prospective cohort study based on primary care practices and thus offers distinct 
advantages over prior studies. Data were collected by primary care physicians who were not 
aware of the hypothesis of the underlying study. Cancer mortality was assessed by reports 
submitted by primary care physicians and also confirmed by examination of death certificates. 
Data were stored and analyzed by blinded personnel. The number of participants in the study 
is large enough to provide adequate statistical power. Thus, our results are generalizable to the 
central European population who formed the study base for the DETECT cohort.  
 
The weaknesses of the study include a relatively short follow-up period of 4 to 5 years. 
Therefore, potential long-term effects of the medications remain unknown. Information 
concerning duration and dose of diabetes medication was not recorded in the described study. 
The number of incident cancer cases in patients with and without type 2 diabetes mellitus is 
small because of the overall design of the study and the relatively short follow-up period. 
However, the analyses showed clearly significant results calling for larger studies to further 
describe the effects of glucose-lowering medications.  
 
Furthermore, the assessment of cancer prevalence or incidence was based on a clinical rating 
in a standardized questionnaire administered by the physicians. It is thus possible that subjects 
with suboptimal follow-up might have provided incomplete information with respect to 
cancer incidence and prevalence. However, there is no evidence that people on metformin 
would have a different follow-up for their diabetes than those on other medications; hence, we 
do not anticipate bias in this respect. Moreover, we have adjusted for a surrogate marker of 
appropriate follow-up (ie, glycemic control, HbA1c) in addition to socioeconomic and 
demographic variables and we have detected no major confounding on the basis of these 
variables. We expect limited misclassification of reporting of medications. Any such 
misclassification would be expected to be random and would have resulted in suppressed 
effect estimates and lower P values, but it could not have resulted in the statistically 
significant results observed herein. Although this is a prospective cohort study that 
incorporates the time sequence criterion for causality, its observational nature cannot prove 
causality beyond any doubt.  
 
These findings are of clinical importance given the dramatically increasing prevalence of type 
2 diabetes mellitus during the last decades; according to the World Health Organization, the 
current prevalence of type 2 diabetes mellitus is approximately 170 million people and the 
number is expected to rise up to 360 million worldwide by the year 2030 [4,21]. If our data 
are extrapolated to people with diabetes in other nations and continents, this would result in a 
much higher prevalence of malignancies in the future. Thus, in addition to larger and longer 
observational cohort studies and larger cohort studies, randomized, placebo-controlled 
metformin administration trials are needed to assess any beneficial effects of metformin in 
relation to cancer-related mortality among diabetic patients. If causality is proven by future 
interventional studies, metformin may emerge as a potential preventive therapy. 
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